Good afternoon! The launch of the closely watched Alzheimer's drug Leqembi is off to a slow start. Still, demand for the treatment from Biogen and its Japanese partner Eisai is rising. That's the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results